[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bevacizumab\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bevacizumab":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,40,71,97,126,152,181,214,238,267,291,315],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":4},"100634753","phase-2-efficacy-and-safety-of-low-dose-bevacizumab-plus-adebrelimab-combined-with-transarterial-chemoembolization-followed-by-hepatic-arterial-infusion-chemotherapy-tace-haic-as-first-line-treatment-for-unresectable-hepatocellular-carcinoma-a-single-arm-phase-2-trial-100634753",false,"NCT07543783","Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 Trial","Inclusion Criteria:\n\nWilling to participate and provide written informed consent. Age ≥ 18 years (on the day of signing informed consent). Histologically or cytologically confirmed hepatocellular carcinoma (HCC), or clinical diagnosis of HCC according to AASLD criteria in patients with cirrhosis.\n\nEligible for TACE, including BCLC stage B or C, with unresectable HCC (excluding PVTT-Vp4 and extrahepatic metastasis).\n\nNo prior systemic therapy for HCC. Eastern Cooperative Oncology Group (ECOG) performance status 0-1. Child-Pugh score A or B7. No history of autoimmune disease. Life expectancy ≥ 3 months. At least one measurable lesion per RECIST v1.1 (spiral CT scan long diameter ≥ 10 mm or short diameter of enlarged lymph node ≥ 15 mm; lesions previously treated with locoregional therapy can be considered target lesions only if progression per RECIST v1.1 is clearly documented).\n\nAdequate hematologic, hepatic, and renal function within 7 days prior to enrollment:\n\nNeutrophils ≥ 1.5 × 10⁹\u002FL Platelets ≥ 50 × 10⁹\u002FL Hemoglobin ≥ 90 g\u002FL ALT\u002FAST ≤ 5 × ULN Serum creatinine ≤ 1.5 × ULN INR \\\u003C 2.3 or prothrombin time ≤ ULN + 6 seconds Albumin ≥ 30 g\u002FL Total bilirubin ≤ 3 × ULN Females of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to enrollment and must not be lactating; they and male participants must agree to use effective contraception during the study and for 6 months after study completion\n\nExclusion Criteria:\n\nKnown cholangiocarcinoma, sarcomatoid HCC, mixed cell carcinoma, or fibrolamellar carcinoma. Active malignancy other than HCC within 5 years, excluding cured localized tumors such as basal cell skin cancer, squamous cell skin cancer, superficial bladder cancer, prostate carcinoma in situ, cervical carcinoma in situ, or breast carcinoma in situ.\n\nSevere allergy to iodine contrast precluding TACE-HAIC. Use of immunosuppressants or systemic corticosteroids for immunosuppressive purposes within 1 month prior to enrollment.\n\nActive uncontrolled infection. Severe gastroesophageal varices; untreated or incompletely treated varices (with bleeding or high bleeding risk).\n\nBrain metastases or bone metastases requiring urgent surgical or radiation intervention.\n\nPregnant, suspected pregnancy, or breastfeeding. Current or recent use (within 10 days prior to study treatment) of aspirin (\\> 325 mg\u002Fday) or dipyridamole, ticlopidine, clopidogrel, or cilostazol.\n\nThromboembolic events within 6 months prior to study treatment, including cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), pulmonary embolism, etc.\n\nCongenital or acquired immunodeficiency. Myocardial infarction, severe\u002Funstable angina, or congestive heart failure within 12 months prior to study start.\n\nRenal insufficiency requiring dialysis. History of organ transplantation. Any other serious acute or chronic medical or psychiatric condition, or laboratory abnormality that would increase the risk of study participation or interfere with interpretation of results.","ALL","18 Years",{"count":18,"type":19},38,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","his is a single-arm, phase II clinical study evaluating the efficacy and safety of low-dose bevacizumab (7.5 mg\u002Fkg, Q3W) plus adebrelimab (1200 mg, Q3W) combined with transarterial chemoembolization (TACE) followed by hepatic arterial infusion chemotherapy (HAIC) with the FOLFOX regimen as first-line treatment for patients with unresectable hepatocellular carcinoma (HCC). Eligible participants will receive TACE followed by HAIC (oxaliplatin, leucovorin, and fluorouracil) and subsequent intravenous administration of adebrelimab and low-dose bevacizumab every 3 weeks. The primary endpoint is objective response rate (ORR) assessed by investigators per RECIST v1.1. Secondary endpoints include progression-free survival (PFS), disease control rate (DCR), duration of response (DoR), overall survival (OS), and safety. A total of 38 participants will be enrolled using Simon's two-stage optimal design (alpha=0.05, power=0.8). The study is sponsored by the Third Affiliated Hospital of Sun Yat-sen University. Adebrelimab is provided free of charge for two years by Shanghai Shengdi Pharmaceutical Co., Ltd.",[25,26,27],"Adebrelimab (SHR-1316)","Bevacizumab","Hepatocellular Carcinoma (HCC)","NOT_YET_RECRUITING","2026-04-22",{"date":31,"type":32},"2026-04-28","ACTUAL",{"date":34,"type":19},"2026-04-10",{"date":36,"type":19},"2029-08-31",{"name":38,"class":39},"Third Affiliated Hospital, Sun Yat-Sen University","OTHER",{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":20,"phases":49,"briefSummary":51,"conditions":52,"keywords":57,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100629985","phase-3-bevacizumab-plus-fsrt-versus-hippocampus-avoidant-wbrt-in-lung-adenocarcinoma-with-extensive-brain-metastases-100629985","NCT07481786","Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases","Application of Bevacizumab Combined With Fractionated Stereotactic Radiotherapy (FSRT-Bev) Versus Hippocampus-Avoidant Whole-Brain Radiotherapy With Simultaneous Integrated Boost (HA-WBRT-SIB) in Patients With Extensive Brain Metastases From Lung Adenocarcinoma: A Phase III Randomized Controlled Trial Evaluating Intracranial Control Efficacy and Neurocognitive Function","Inclusion Criteria:\n\n* Age ≥18 years\n* Pathologically confirmed non-squamous non-small cell lung cancer (adenocarcinoma)\n* Extensive brain metastases meeting any of the following:\n\n1-2 metastases with at least one ≥3 cm in diameter; or 3-10 metastases with at least one ≥2 cm; or 11-20 metastases\n\n* Stable extracranial disease\n* ECOG performance status 0-2\n* Adequate bone marrow, hepatic, and renal function\n* Written informed consent\n\nExclusion Criteria:\n\n* Contraindications to bevacizumab (uncontrolled hypertension, history of bleeding\u002Fthromboembolism, recent surgery, etc.)\n* Leptomeningeal metastasis\n* Prior brain radiotherapy or surgical resection of brain metastases\n* Significant mass effect requiring urgent neurosurgical intervention\n* Severe cardiovascular, vascular, or gastrointestinal disease within 6 months\n* Proteinuria ≥3+ or 24-hour urine protein \\>1 g\n* Other active malignancies (except curable non-melanoma skin cancer or cervical carcinoma in situ)\n* Inability to comply with neurocognitive testing\n* Pregnancy or breastfeeding",{"count":48,"type":19},220,[50],"PHASE3","This is a phase 3, randomized, controlled clinical trial comparing two brain-directed treatment strategies for adult patients with extensive brain metastases from lung adenocarcinoma. The trial compares fractionated stereotactic radiotherapy combined with bevacizumab (FSRT-Bev) versus hippocampus-avoidant whole-brain radiotherapy with simultaneous integrated boost (HA-WBRT-SIB). The main objectives are to evaluate intracranial tumor control and preservation of neurocognitive function .\n\nPatients will be randomly assigned in a 1:1 ratio to receive either FSRT plus bevacizumab or HA-WBRT-SIB. In the experimental group, FSRT is delivered to visible brain tumors over 5 daily treatments (total 30 Gy, 6 Gy per fraction). Bevacizumab is given intravenously every 3 weeks for 4 cycles. In the control group, patients receive hippocampus-avoidant whole-brain radiation (25 Gy) with a simultaneous dose boost to metastatic lesions (40 Gy total) over 10 daily treatments.",[53,54,55,26,56],"Lung Adenocarcinoma","Brain Metastases","Radiotherapy, Intensity-Modulated","Whole-Brain Radiotherapy",[53,54,58,26,59],"fractionated stereotactic radiotherapy (FSRT)","Whole-brain radiotherapy with simultaneous integrated boost (HA-WBRT-SIB)","RECRUITING","2026-04-03",{"date":63,"type":32},"2026-04-06",{"date":65,"type":32},"2026-03-20",{"date":67,"type":19},"2029-09-15",{"name":69,"class":39},"Sun Yat-sen University",3,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":20,"phases":79,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":96},"100618143","phase-2-ql1706-in-combination-with-bevacizumab-and-ralox-haic-for-hepatocellular-carcinoma-with-vp34-pvtt-100618143","NCT07327788","QL1706 in Combination With Bevacizumab and RALOX HAIC for Hepatocellular Carcinoma With Vp3\u002F4 PVTT","Iparomlimab and Tuvonralimab (QL1706) With Bevacizumab and RALOX Hepatic Arterial Infusion Chemotherapy for Hepatocellular Carcinoma (HCC) With Vp3\u002F4 Portain Vein Thrombosis : A Prospective, Multicenter, Phase II Study","Inclusion Criteria:\n\n1. Voluntarily sign the informed consent form;\n2. Aged ≥ 18 years, male and female subjects are both eligible;\n3. Clinically or pathologically confirmed hepatocellular carcinoma (HCC), with no prior systemic anti-tumor therapy for HCC (including but not limited to molecular targeted therapy, systemic chemotherapy, immunotherapy such as anti-PD-1\u002FPD-L1\u002FCTLA-4 monoclonal antibodies, etc.);\n4. Complicated with Type VP3 or VP4 portal vein tumor thrombosis (PVTT);\n5. Confirmed to have at least one measurable target lesion by imaging examination during the screening period in accordance with RECIST v1.1 criteria. The measurable lesions should not have received local treatment such as radiotherapy (lesions within the area of previous local treatment can also be selected as target lesions if disease progression is confirmed);\n6. Child-Pugh score ≤ 7 points (Child-Pugh class A-B);\n7. The maximum diameter of liver tumor ≥ 7 cm;\n8. ECOG performance status 0 to 1;\n9. Expected survival time ≥ 12 weeks;\n10. Function of vital organs meeting the following requirements:\n\nAbsolute neutrophil count (ANC) ≥ 1.5×10⁹\u002FL; Platelet count ≥ 50×10⁹\u002FL; Hemoglobin ≥ 90 g\u002FL; Serum albumin ≥ 29 g\u002FL; Bilirubin ≤ 2 × upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 × ULN, alkaline phosphatase (AKP) ≤ 5 × ULN; Serum creatinine ≤ 1.5 × ULN or creatinine clearance rate (CrCl) ≥ 50 mL\u002Fmin calculated by the Cockcroft-Gault formula; 11.Eligible patients with reproductive potential (males and females) must agree to use a reliable contraceptive method (hormonal, barrier method or abstinence) with their partners during the trial and for at least 180 days after the last dose; female patients of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first study medication administration.\n\nExclusion Criteria:\n\n1. Histologically or cytologically confirmed fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, cholangiocellular carcinoma, mixed hepatocellular carcinoma, etc.;\n2. Active autoimmune disease, or a history of autoimmune disease with potential for recurrence (including but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism \\[patients whose condition is controllable only with hormone replacement therapy are not excluded\\]); Note: Patients with dermatological diseases that do not require systemic treatment (e.g., vitiligo, psoriasis, alopecia), type 1 diabetes with good glycemic control under insulin therapy, or asthma that achieved complete remission in childhood and requires no intervention in adulthood are eligible for enrollment; patients with asthma requiring medical intervention with bronchodilators are ineligible.\n3. Administration of immunosuppressants or systemic hormonal therapy for immunosuppressive purposes within 2 weeks prior to the first study medication (dose \\> 10 mg\u002Fday prednisone or an equivalent dose of other hormones);\n4. Current interstitial pneumonia or interstitial lung disease, a history of interstitial pneumonia or interstitial lung disease requiring hormonal therapy, or other pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), pneumoconiosis, drug-related pneumonia, idiopathic pneumonia that may interfere with the judgment and management of immune-related pulmonary toxicity; patients with evidence of active pneumonia on screening CT or severe impairment of pulmonary function are excluded. Radiation pneumonitis within the radiation field is permitted;\n5. Confirmed active pulmonary tuberculosis. For subjects with suspected active pulmonary tuberculosis, a definitive diagnosis shall be made based on chest imaging, sputum examination, and clinical symptoms and signs;\n6. Known hypersensitivity to the active ingredients or excipients of the study drugs, or a history of severe hypersensitivity to any other monoclonal antibody or anti-angiogenic targeted drugs;\n7. Known history of central nervous system (CNS) metastasis or hepatic encephalopathy;\n8. A history of allogeneic stem cell transplantation or solid organ transplantation;\n9. Moderate to severe ascites with clinical symptoms requiring therapeutic paracentesis or drainage (except for patients with only a small amount of ascites shown by imaging without clinical symptoms), or uncontrolled moderate to large pleural effusion or pericardial effusion;\n10. Severe cardiovascular and cerebrovascular diseases, including but not limited to:\n\n(1) Severe cardiac rhythm or conduction abnormalities (e.g., ventricular or supraventricular arrhythmias requiring clinical intervention, grade Ⅱ-Ⅲ atrioventricular block), QTcF interval ≥ 450 ms (males) or QTcF interval ≥ 470 ms (females) (if the QTcF interval is abnormal at screening, two additional tests shall be performed at an interval of at least 5 minutes, and the average value shall be taken); unstable angina pectoris, etc.; (2) Acute coronary syndrome, congestive heart failure, aortic dissection, stroke, transient ischemic attack (TIA) or other grade 3 and above cardiovascular and cerebrovascular events within 6 months prior to the first study medication; (3) New York Heart Association (NYHA) cardiac function classification ≥ grade II or left ventricular ejection fraction (LVEF) \\\u003C 50%; (4) Poorly controlled hypertension (systolic blood pressure ≥ 160 mmHg and\u002For diastolic blood pressure ≥ 100 mmHg after treatment with two or more antihypertensive drugs); 11.Coagulation dysfunction (INR \\> 2.0, prothrombin time (PT) prolonged by more than 6 seconds), with obvious bleeding tendency or other evidence of major coagulation disorders: clinically significant hemoptysis or tumor bleeding of any cause within 2 weeks prior to the first study medication; a history of thrombosis or embolism within 6 months prior to the first study medication; therapeutic anticoagulant therapy (except low-molecular-weight heparin) within 2 weeks prior to the first study medication; or antiplatelet therapy (e.g., aspirin \\> 325 mg\u002Fday, clopidogrel \\> 75 mg\u002Fday, dipyridamole, ticlopidine, cilostazol) within 10 days prior to the first study medication, or patients requiring long-term antiplatelet therapy; patients with metastatic lesions invading large blood vessels, respiratory tract or middle mediastinum with a significant risk of bleeding; 12.A history of esophageal or gastric variceal bleeding caused by portal hypertension within 6 months prior to the first study medication; confirmed severe varices by endoscopy within 3 months prior to the first study medication; or evidence of portal hypertension (including splenomegaly detected by imaging) with a high risk of bleeding assessed by the investigator (including moderate to severe esophagogastric varices with bleeding risk, active local peptic ulcer, and persistent positive fecal occult blood, which require gastroscopy to exclude patients with \"red signs\". Patients with a history of \"red signs\" on gastroscopy are excluded); 13.Any life-threatening bleeding event within 3 months prior to the first study medication, including those requiring blood transfusion, surgery or local treatment, and continuous drug therapy; 14.A history of abdominal fistula, gastrointestinal perforation or abdominal abscess within 6 months prior to the first study medication; 15.A history of intestinal obstruction and\u002For clinical signs or symptoms of gastrointestinal obstruction within 6 months prior to the first study medication, including incomplete obstruction related to the primary disease or requiring routine parenteral hydration, parenteral nutrition or tube feeding; 16.Severe unhealed wounds, active ulcers or untreated fractures; 17.Urinalysis showing urine protein ≥ ++ with a confirmed 24-hour urine protein excretion \\> 1.0 g; 18.Severe infection within 4 weeks prior to the first study medication (including but not limited to hospitalization due to infection, bacteremia or severe pneumonia complications); active infection requiring oral or intravenous therapeutic antibiotics within 2 weeks prior to the first study medication (patients receiving prophylactic antibiotics, e.g., for prevention of urinary tract infection or acute exacerbation of chronic obstructive pulmonary disease, are eligible); unexplained fever ≥ 38.5℃ within 7 days prior to medication administration, or baseline white blood cell count \\> 15×10⁹\u002FL; 19.Congenital or acquired immune deficiency (e.g., HIV-infected patients), or confirmed active syphilis infection; 20.A history of other malignant tumors except HCC within 5 years prior to the first study medication or concurrent malignant tumors. Patients with the following cured localized tumors are eligible for enrollment: basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, carcinoma in situ of the prostate, carcinoma in situ of the cervix, carcinoma in situ of the breast, etc.; 21.Hepatic surgery, local treatment for HCC or investigational drug therapy within 4 weeks prior to the first study medication; administration of traditional Chinese medicine preparations with anti-HCC effects within 2 weeks prior to the first study medication; or toxic reactions caused by previous treatment (except alopecia) that have not recovered to ≤ grade 1 (per NCI-CTCAE v5.0); 22.Administration of drugs with immunomodulatory effects (including but not limited to interferon, interleukin) within 2 weeks prior to the first study medication; 23.Participation in other clinical studies and administration of other investigational drugs within 4 weeks prior to the first study medication; 24.Administration of live attenuated vaccines within 4 weeks prior to the first study medication, or anticipated need for such vaccination during the study treatment or within 90 days after the last study medication; 25.Major surgery (except for diagnostic purposes) within 4 weeks prior to the first study medication, or anticipated major surgery during the study period (major surgery is defined as surgery performed under general anesthesia that requires a recovery period of at least 3 weeks before initiation of study drug treatment); tissue biopsy or other minor surgical procedures within 7 days prior to the first study medication, except for venous catheterization for intravenous infusion; 26.Pregnant or lactating women, or women of childbearing potential who refuse to take contraceptive measures; 27.Other factors judged by the investigator that may affect the study results or lead to forced early termination of the study, such as alcoholism, drug abuse, other severe diseases (including mental illness) requiring combined treatment, severe abnormal laboratory tests, or family\u002Fsocial factors that may affect patient safety.",{"count":18,"type":19},[22],"The goal of this prospective, single-arm, multi-center Phase II clinical trial is to evaluate the clinical efficacy and safety of QL1706 combined with bevacizumab and RALOX hepatic artery infusion chemotherapy in treating liver cancer patients with VP3\u002F4 portal vein tumor thrombus. It will also explore molecular biomarkers that predict the efficacy of this combined therapy.\n\nThe main questions it aims to answer are:\n\nWhat is the progression-free survival (PFS) of patients treated with this regimen? What are the objective response rate (ORR), disease control rate (DCR), and overall survival (OS) of these patients? What is the safety and tolerability profile of this combined treatment? Which molecular biomarkers can predict the efficacy of this therapy? Eligible subjects (who have signed informed consent) will receive RALOX hepatic artery infusion chemotherapy plus QL1706 (7.5mg, intravenous infusion every 3 weeks) and bevacizumab (15mg\u002Fkg, intravenous infusion every 3 weeks), with 3 weeks as one treatment cycle. Treatment will continue until a protocol-specified discontinuation event occurs. After treatment, subjects will undergo post-treatment safety follow-up and survival follow-up; those who discontinue treatment for reasons other than disease progression or death will also have tumor progression follow-up.",[82,83,26,84,85,86],"Hepatecellular Carcinoma","RALOX-HAIC（Hepatic Arterial Infusion Chemotherapy With Raltitrexed and Oxaliplatin","Type VP3\u002F4 Portal Vein Tumor Thrombosis","Iparomlimab and Tuvonralimab Injection","QL1706","2026-01-11",{"date":89,"type":32},"2026-01-13",{"date":91,"type":19},"2025-12-25",{"date":93,"type":19},"2028-12-30",{"name":95,"class":39},"Nanfang Hospital, Southern Medical University",1,{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":107,"phases":4,"briefSummary":108,"conditions":109,"keywords":112,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":96},"100540940","locoregional-therapy-combined-with-bevacizumab-and-pd1l1-inhibitor-in-advanced-hepatocellular-carcinoma-100540940","NCT06323382","Locoregional Therapy Combined With Bevacizumab and PD1\u002FL1 Inhibitor in Advanced Hepatocellular Carcinoma","Efficacy of Locoregional Therapy Combined With Bevacizumab and PD1\u002FL1 Inhibitor in Advanced Hepatocellular Carcinoma: a Multicenter, Observational, Real-world Study","Inclusion Criteria:\n\n1. HCC diagnosed by histopathological examination or Guidelines for Diagnosis and Treatment of Primary Liver Cancer or the recurrent HCC after surgery;\n2. age between 18 and 75 years;\n3. Stage B (middle stage) or C (late stage) HCC determined in accordance with Barcelona Clinic Liver Cancer staging system (BCLC stage).\n4. Locoregional therapy include TACE or HAIC, locoregional combined with Bevacizumab and PD1\u002FL1 inhibitor as firstline therapy; non-firstline therapy (previous use of any systemic therapy but intolerant or drug resistant).\n5. Child-Pugh class A or B;\n6. Eastern Cooperative Group performance status (ECOG) score of 0-2;\n7. Hemoglobin ≥ 8.5 g\u002FdL Total bilirubin ≤ 30mmol\u002FL Serum albumin ≥ 32 g\u002FL ASL and AST ≤ 5 x upper limit of normal Serum creatinine ≤ 1.5 x upper limit of normal INR ≤ 1.5 or PT\u002FAPTT within normal limits Absolute neutrophil count (ANC) \\>1,500\u002Fmm3\n8. Prothrombin time ≤18s or international normalized ratio \\\u003C 1.7.\n9. Ability to understand the protocol and to agree to and sign a written informed consent document.\n\nExclusion Criteria:\n\n1. Cholangiocellular carcinoma (ICC).\n2. Patients without image information should be excluded;\n3. The survival or patients less than 3 months.\n4. Serious medical comorbidities.\n5. Evidence of hepatic decompensation including ascites, gastrointestinal bleeding or hepatic encephalopathy.\n6. Known history of HIV.\n7. History of organ allograft.\n8. Known or suspected allergy to the investigational agents or any agent given in association with this trial.\n9. Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.\n10. Evidence of bleeding diathesis.\n11. Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry.","80 Years",{"count":106,"type":19},240,"OBSERVATIONAL","Atezolizumab + Bevacizumab was superior to sorafenib in overall survival in advanced hepatocellular carcinoma. The programmed cell death protein-1 (PD1) and PDL1 inhibitor, was effective and tolerable in patients with advanced hepatocellular carcinoma. We aimed to describe the efficacy and safety of locoregional therapy combined with Bevacizumab and PD1\u002FL1 inhibitor in patients with advanced hepatocellular carcinoma who can not receive radical therapy.",[110,111,26],"Advanced Hepatocellular Carcinoma","Anti-PD1\u002FPDL1 Antibody",[26,113,114,115,116,117],"Atezolizumab","Tislelizumab","Toripalimab","Sintilimab","Camrelizumab","2025-08-10",{"date":120,"type":32},"2025-08-14",{"date":122,"type":32},"2021-01-01",{"date":124,"type":19},"2025-12-30",{"name":69,"class":39},{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":15,"minAge":133,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":20,"phases":136,"briefSummary":137,"conditions":138,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":151},"100599490","phase-2-low-dose-trifluridinetipiracil-with-bevacizumab-in-mcrc-100599490","NCT07085169","Low-dose Trifluridine\u002FTipiracil With Bevacizumab in mCRC","Low-dose Trifluridine\u002FTipiracil With Bevacizumab in Refractory Metastatic Colorectal Cancer: a Multicenter, Single-arm, Phase 2 Study","Inclusion Criteria:\n\n1. age over 60 years old, male and female\n2. histologically confirmed adenocarcinoma of the colon or rectum\n3. patients with metastatic or advanced unresectable diseases who had received two or more previous chemotherapy regimens or intolerance to last regimen\n4. with or without measurable lesions\n5. ECOG 0 to 2, expected survival time over 3 months\n6. Enough organ functions that can tolerate treatment: Absolute neutrophil count (ANC) ≥1.5x109\u002FL, White blood count ≥3.5x109\u002FL, Platelets ≥75x109\u002FL, Hemoglobin (Hb) ≥80g\u002FL, ALT\u002FAST ≤2.5x ULN (for patient with liver metastasis ALT\u002FAST ≤5x ULN), Serum bilirubin ≤1.5x ULN, Serum creatinine ≤1.5x ULN.\n7. Signed informed consent and willing to follow the study protocol\n\nExclusion Criteria:\n\n1. symptomatic metastases of central nervous system\n2. other primary malignancies\n3. uncontrollable comorbidities, such as hypertension, thrombotic diseases, chronic kidney disease\n4. organ functions that cannot tolerate study treatment\n5. bowel obstruction or other conditions affecting oral administration\n6. allergic to study medication\n7. other conditions that patients are unsuitable for this study assessed by the investigators","60 Years",{"count":135,"type":19},50,[22],"This is a phase II, single-center, prospective trial aimed to investigate the efficacy and safety of a modified regimen of trifluridine\u002Ftipiracil plus bevacizumab in refractory metastatic colorectal cancer. Patients will be treated with trifluridine\u002Ftipiracil (17.5 mg\u002Fm2 dose orally twice daily, d1-10, every 14-days) plus bevacizumab (5mg\u002Fkg dose intravenously once at day 1, every 14-days). The study treatment will be administered until progression of disease, intolerable toxicity or withdraw of consent.",[139,140,141,26],"Colo-rectal Cancer","Third-line and Beyond Therapy","TAS 102","2025-07-24",{"date":144,"type":32},"2025-07-25",{"date":146,"type":19},"2025-08-01",{"date":148,"type":19},"2028-08-01",{"name":150,"class":39},"Ruijin Hospital",2,{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":158,"targetDuration":4,"studyType":20,"phases":160,"briefSummary":162,"conditions":163,"keywords":169,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":96},"100593276","phase-4-efficacy-and-safety-of-iparomlimab-and-tuvonralimab-injection-in-combination-with-bevacizumab-after-progression-on-anti-pd-l1-therapy-in-advanced-melanoma-a-prospective-single-arm-exploratory-clinical-study-100593276","NCT07004335","Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study","Inclusion Criteria:\n\nParticipants must meet all of the following criteria for enrollment:\n\n1. Age ≥18 years;\n2. Histologically-confirmed unresectable Stage III or IV melanoma, unsuitable for local therapy;\n3. Confirmed PD according to iRECIST within 12 weeks after receiving the last dose of anti-PD-(L)1 monotherapy or in combination with other treatments (including anti-CTLA-4) for at least two doses. (Up to 25% of participants may have received both anti-CTLA-4 and anti-PD-(L)1 treatment);\n4. Participants with BRAF\u002FCKIT\u002FNRAS gene mutations must have progressed after targeted therapy;\n5. Intolerant to chemotherapy or refused standard therapy;\n6. Toxicity from the most recent treatment recovered to grade 1 or below (except alopecia); if participants underwent major surgery or radiotherapy \\>30 Gy, they must have recovered from treatment-related toxicities\u002Fcomplications;\n7. Life expectancy of at least 3 months;\n8. Eastern Cooperative Oncology Group (ECOG) score: 0-1;\n9. At least one measurable lesion confirmed according to RECIST 1.1 criteria;\n10. Laboratory test results at screening must meet the following requirements:\n\n    a) Hematological tests must meet the following criteria (no blood\u002Fblood product transfusion, no correction with G-CSF or other hematopoietic stimulants within 14 days): i. Hemoglobin (Hb) ≥ 90 g\u002FL ii. Neutrophil count (ANC) ≥ 1.5 × 10\\^9\u002FL iii. Platelet count (PLT) ≥ 100×10\\^9\u002FL b) Biochemical tests must meet the following criteria: i. Total bilirubin (TBIL) \\\u003C 1.5 × upper limit of normal (ULN) ii. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \\\u003C 2.5 ULN (\\\u003C5 ULN for participants with liver metastasis) iii. Serum creatinine (Cr) ≤ 1.5 ULN or endogenous creatinine clearance rate \\> 50ml\u002Fmin (Cockcroft-Gault formula) iv. Urine routine test results show urine protein (UPRO) \\\u003C 2+ or 24-hour urine protein quantification \\\u003C1g;\n11. Women of childbearing potential must have taken reliable contraceptive measures, had a negative pregnancy test (serum or urine) within 7 days before enrollment, and agree to use appropriate contraception during the trial and for 6 months after the last administration of the investigational drug. Nursing mothers should discontinue breastfeeding during the whole trial period and for 6 months after the last administration of the investigational drug to avoid the drug affecting the infant through milk. For men, they must agree to use appropriate contraception during the trial and for 120 days after the last administration of the investigational drug or have undergone surgical sterilization;\n12. Provide written informed consent, and are expected to have good compliance with the study protocol.\n\nExclusion Criteria:\n\nParticipants meeting any of the following will be excluded:\n\n1. Any active autoimmune disease or a history of autoimmune disease requiring treatment (including but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, colitis, hepatitis, pituitary炎, vasculitis, nephritis, hyperthyroidism; participants with vitiligo; childhood asthma that has completely resolved without any intervention in adulthood can be included; participants with asthma requiring bronchodilators for medical intervention cannot be included);\n2. Received more than 10 mg of prednisolone or other immunosuppressive therapy within seven days prior to study treatment;\n3. Severe allergic reaction to other monoclonal antibodies;\n4. Uncontrolled cardiac clinical symptoms or disease, such as: heart failure of NYHA class 2 or above; unstable angina; myocardial infarction within the past year; clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention; QTc \\>450 ms (males); QTc \\>470 ms (females);\n5. Underwent any major surgery requiring general anesthesia within 28 days prior to the first dose;\n6. Active infection, unexplained fever ≥38.5°C within seven days prior to medication, or baseline white blood cell count \\>15×10⁹\u002FL; or suppurative and chronic infections, non-healing wounds;\n7. With bone metastasis who received palliative radiotherapy to \\>5% of the bone marrow area within four weeks prior to study entry;\n8. Known allergy to recombinant humanized anti-PD-(L)1 monoclonal antibody drugs, recombinant humanized anti-CTLA-4 monoclonal antibody, and\u002For their components;\n9. Concurrent other malignancies;\n10. Concurrent participation in other interventional clinical trials;\n11. HIV positive; HCV positive; HBsAg or HBcAb positive with detectable HBV DNA copies (quantitative detection limit of 500 IU\u002Fml);\n12. Received live vaccine vaccination within four weeks prior to treatment initiation;\n13. Ocular melanoma;\n14. With active brain metastasis (previously untreated asymptomatic brain metastasis patients with ≤3 brain lesions and longest diameter \\\u003C1 cm can be included. Previously treated brain metastasis patients who are clinically stable with no new or enlarged brain metastasis and have not used steroids for ≥14 days prior to study intervention can be included); other severe, acute, or chronic medical or mental disorders or laboratory abnormalities that may increase the risk associated with study participation or may interfere with the interpretation of study results, as judged by the investigator.",{"count":159,"type":19},40,[161],"PHASE4","Several studies have shown that the combination of Iparomlimab, Tuvonralimab, and Bevacizumab exhibits potent anti-tumor activity and favorable safety in various solid tumors, including liver cancer. However, the efficacy and safety of this regimen in melanoma patients with acquired resistance to immunotherapy remain unexplored and require further validation.\n\nThis study aims to evaluate the efficacy and safety of the Iparomlimab, Tuvonralimab, and Bevacizumab combination in patients with immune-resistant melanoma. Furthermore, it will analyze and compare treatment responses among different melanoma subtypes to identify optimal treatment strategies for clinical practice.",[164,165,166,167,168,26],"PD-(L)1","CTLA-4","Advanced Melanoma","Iparomlimab","Tuvonralimab",[170,171],"Immunotherapy","Immune Checkpoint Inhibitors","2025-05-27",{"date":174,"type":32},"2025-06-04",{"date":176,"type":19},"2025-07-01",{"date":178,"type":19},"2029-01-31",{"name":180,"class":39},"Hebei Medical University Fourth Hospital",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":20,"phases":190,"briefSummary":191,"conditions":192,"keywords":200,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":96},"100574161","phase-2-neoadjuvant-befotertinib-combined-bevacizumab-or-platinum-based-double-chemotherapy-for-resectable-locally-advanced-egfr-mutation-positive-non-small-cell-lung-cancer-100574161","NCT06755684","Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer","Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer: a Single-center, Randomized Controlled Trial","Inclusion Criteria:\n\n* NSCLC patient with EGFR sensitive mutation as confirmed by needle biopsy;\n* At stage II-IIIA (TNM Staging, Version 8) as identified by chest CT, PET-CT or\u002Fand EBUS;\n* No systemic metastasis (confirmed by head MRI, whole body bone scan, PET-CT, liver and adrenal CT, etc.);\n* With the feasibility to receive radical surgery ;\n* Good lung function that could tolerate surgical treatment;\n* Aged 18-75 years;\n* At least one measurable tumor foci (the longest diameter measured by CT shall be \\> 10 mm);\n* Other major organs shall function well (liver, kidney, blood system, etc.):\n* ECOG PS score shall be 0-1;\n* The child-bearing female must undergo pregnancy test within 7 days before starting the treatment and the result shall be negative. Reliable contraceptive measures, such as intrauterine device, contraceptive pill and condom, shall be adopted during the trial and within 30 days after completion of the trial. The child-bearing male shall use condom for contraception during the trial and within 30 days after completion of the trial;\n* The patient shall sign the Informed Consent Form.\n\nExclusion Criteria:\n\n* The patient has undergone any systemic anti-cancer treatment for NSCLC, including surgical treatment, local radiotherapy, cytotoxic drug treatment, targeted drug treatment and experimental treatment, etc.;\n* The patient suffers from any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina pectoris, angina pectoris that starts to attack within the last 3 months, congestive heart failure \\[≥ Grade II specified by New York Heart Association (NYHA)\\], cardiac infarction (6 months before enrollment), severe arrhythmia and liver, kidney or metabolic diseases that requires drug treatment;\n* The patient is a carrier of HIV;\n* The patient has had or is currently suffering from interstitial lung disease;\n* The patient had undergone other major systemic operations or suffered from severe trauma within 3 months before the trial;\n* The patient is allergic to befotertinib or its any excipients;\n* The patient is allergic to bevacizumab or its any excipients;\n* The patient is allergic to platinum-based double chemotherapy or its any excipients;\n* The female patient is in pregnancy or lactation period;\n* There are any conditions under which the investigator considers the patient is not suitable to be enrolled.",{"count":189,"type":19},60,[22],"This study targeted patients with resectable stage II-IIIA non-small cell lung cancer with EGFR mutation",[193,194,195,196,197,26,198,199],"EGFR","Non-Small Cell Lung Cancer","Locally Advanced Non-Small Cell Lung Cancer","Pemetrexed","Carboplatin","Antineoplastic Agents","Tyrosine Kinase Inhibitor",[201,202,203,26,204],"EGFR-TKI","NSCLC","Chemotherapy","Locally advanced non-small cell lung cancer","2025-01-03",{"date":207,"type":32},"2025-01-06",{"date":209,"type":32},"2024-11-07",{"date":211,"type":19},"2028-12-31",{"name":213,"class":39},"Peng Zhang",{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":4,"eligibilityCriteria":220,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":221,"enrollmentInfo":222,"targetDuration":4,"studyType":20,"phases":224,"briefSummary":226,"conditions":227,"keywords":228,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":96},"100562953","dtace-haic-combined-with-bevacizumab-and-atezolizumab-for-huge-hepatocellular-carcinoma-100562953","NCT06609863","dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Hepatocellular Carcinoma","dTACE-HAIC Combined With Bevacizumab and Atezolizumab for Huge Intermediate and Advanced Hepatocellular Carcinoma: a Prospective Phase II Study","Inclusion Criteria:\n\n1. Clinical diagnosis of HCC.\n2. Age between 18 and 75 years;\n3. The maximum tumor size ≥10 cm;\n4. Intermediate-advanced huge HCC, advanced HCC with PVTT type I-III\n5. limited metastases (≤5).\n6. Child-Pugh class A or B;\n7. Eastern Cooperative Group performance status (ECOG) score of 0-1;\n8. Hemoglobin ≥ 8.5 g\u002FdL Total bilirubin ≤ 30mmol\u002FL Serum albumin ≥ 32 g\u002FL ASL and AST ≤ 5 x upper limit of normal Serum creatinine ≤ 1.5 x upper limit of normal INR ≤ 1.5 or PT\u002FAPTT within normal limits Absolute neutrophil count (ANC) \\>1,500\u002Fmm3\n9. Prothrombin time ≤18s or international normalized ratio \\\u003C 1.7.\n10. Ability to understand the protocol and to agree to and sign a written informed consent document.\n\nExclusion Criteria:\n\n1. Diffuse HCC;\n2. Extrahepatic metastasis \\>5;\n3. Obstructive PVTT involving mesenteric vena cava (PVTT IV).\n4. Serious medical comorbidities.\n5. Evidence of hepatic decompensation including ascites, gastrointestinal bleeding or hepatic encephalopathy\n6. untreated or incompletely treated esophageal or gastric varices (assessed with esophagogastroduodenoscopy) with bleeding or high risk of bleeding.\n7. Eastern Cooperative Group performance status (ECOG) score of ≥2;\n8. Known or suspected allergy to the investigational agents or any agent given in association with this trial.\n9. Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy\n10. Evidence of bleeding diathesis.\n11. Patients with clinically significant gastrointestinal bleeding within 30 days prior to study entry.","75 Years",{"count":223,"type":19},27,[225],"NA","This study intends to evaluate the efficacy and safety of drug-eluting transcatheter arterial embolization-hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin (dTACE-HAIC) plus Bevacizumab and Atezolizumab for patients with intermediate-advanced huge hepatocellular carcinoma.",[110,113,26,203],[229,113,26],"hepatocellular carcinoma","2024-12-01",{"date":232,"type":32},"2024-12-03",{"date":234,"type":32},"2024-10-01",{"date":236,"type":19},"2026-06-30",{"name":69,"class":39},{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":4,"eligibilityCriteria":244,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":221,"enrollmentInfo":245,"targetDuration":4,"studyType":20,"phases":246,"briefSummary":247,"conditions":248,"keywords":252,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":263,"leadSponsor":265,"locationsCount":70},"100557549","phase-2-efficacy-and-resistant-mechanism-of-eribulin-and-bevacizumab-for-advanced-her2-negative-breast-cancer-100557549","NCT06539559","Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer","Efficacy, Adverse Events and Resistant Mechanism of Eribulin Combined With or Without Bevacizumab for Advanced HER2 Negative Breast Cancer Patients, an Open-label, Randomized, Multi-center PhaseⅡ Clinical Trial.","Inclusion Criteria:\n\n1. Age ≥18 years old，and ≤75 years old.\n2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n3. Expected survival period not less than 12 weeks.\n4. At least 1 measurable lesion according to RECIST 1.1 standard.\n5. previously treated with taxanes and\u002For anthracycline drugs in any stage of breast cancer.\n6. Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) validated HER2 negative, including IHC- and IHC 1+\u002F2+ with FISH negative.\n7. at least prior 1 line of chemotherapy in the advanced stage.\n8. The organ function must meet the following requirements：\n\n(1). Blood Routine\n\n* ANC≥1.5×109\u002FL；\n* PLT≥90×109\u002FL；\n* Hb≥90 g\u002FL；\n\n  (2). Blood Biochemistry\n* TBIL≤1.5×ULN；\n* ALT and AST≤2×ULN；ALT和AST≤5×ULN for patients with liver metastasis；\n* BUN and Cr≤1.5×ULN and the Creatinine Clearance Rate ≥50 mL\u002Fmin (Cockcroft-Gault formula calculated)；\n\n  (3). Echocardiogram\n* LVEF≥50%；\n\n  (4). electrocardiogram\n* The QT interval (QTcF) corrected by Fridericia method less than 450 ms for male and less than 470 ms for female.\n\n  9\\. Volunteer to join this study, sign informed consent, have good compliance and be willing to cooperate with follow-up.\n\nExclusion Criteria:\n\n1. There is a third interstitial fluid accumulation that cannot be controlled by drainage or other methods (such as a large amount of hydrothorax and ascites).\n2. Symptomatic or uncontrolled brain or meningeal metastases.\n3. Patients with only bone or skin metastasis as the assessable lesion.\n4. Previously suffered from other malignant tumors.\n5. Those who have used Eribulin during the advanced disease stage.\n6. Individuals with a known history of allergies to the components of the interventions; History of immunodeficiency, including HIV positive, other acquired or congenital immunodeficiency diseases and a history of organ transplantation.\n7. Any heart disease or other conditions evaluated unsuitable by the researcher.\n8. Pregnant and lactating female patients, female patients with fertility and positive baseline pregnancy test results, or female patients of reproductive age who are unwilling to take effective contraceptive measures throughout the trial period.\n9. According to the investigator's judgment, there are concomitant diseases that seriously endanger the patient's safety or affect the patient's completion of the study (including severe bleeding tendency, history of surgery within 2 weeks, hypertension beyond drug control, serious diabetes, active infection, thyroid disease, etc.).\n10. Having a clear history of neurological or mental disorders, including epilepsy or dementia.\n11. According to the RECIST 1.1 criteria, researchers determined that patients who received the last anti-tumor regimen before enrollment did not experience disease progression.",{"count":189,"type":19},[22],"This study is a prospective, multicenter, phase II randomized clinical trial. It is planned to enroll 60 patients with advanced HER2 negative breast cancer, who will be randomly assigned to the experimental group and the control group in a 1:1 ratio. The participants will receive either eribulin combined with bevacizumab or eribulin monotherapy. Every treatment cycle will last for 21 days, with weekly monitoring of blood routine, blood biochemistry and other indicators. Imaging examinations will be conducted every two cycles and the efficacy will be evaluated according to RECIST 1.1 standard. The life quality questionnaire is arranged at baseline and every 3 months after enrollment, and the long-time survival will be followed every 3 months after treatment. The primary endpoint is progression-free survival (PFS), the secondary endpoints are objective response rate (ORR), clinical benefit rate (CBR) and overall survival (OS). The investigators will also focus on the treatment-related adverse events (TRAE) and quality of life (QoL) assessment.\n\nAt the same time, this study also aims to explore the resistant mechanisms of anti-angiogenic drugs. The investigators plan to collect peripheral venous blood samples at 3 time points: baseline, during treatment, and end of treatment. All the dynamic samples will be used for transcriptome sequencing to obtain the gene sets. And based on the optimal therapeutic efficacy, all the participants will be divided into response group and non-response group. GO and KEGG enrichment analysis will be subsequently performed between different therapeutic efficacy groups to draw gene interaction networks, identify key action nodes and explain the mechanism of anti-angiogenic drug resistance.",[249,250,251,26],"Breast Neoplasms","Neoplasm Metastasis","Drug Therapy",[253,254,255,256,257,258],"breast cancer","HER2 negative","eribulin","bevacizumab","efficacy","resistant mechanism","2024-08-01",{"date":261,"type":32},"2024-08-06",{"date":259,"type":19},{"date":264,"type":19},"2026-08-01",{"name":266,"class":39},"Wang Jiayu",{"id":268,"slug":269,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":221,"enrollmentInfo":273,"targetDuration":4,"studyType":20,"phases":275,"briefSummary":276,"conditions":277,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":96},"100513837","phase-2-single-arm-prospective-multicenter-clinical-study-of-tace-with-adebrelimab-and-bevacizumab-for-unresectable-hepatocellular-carcinoma-100513837","NCT05970666","Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma","Inclusion Criteria:\n\n1. Age: 18 \\~ 75, both male and female；\n2. Strictly comply with the primary liver cancer diagnosis and treatment standard (2022 edition) clinical diagnosis criteria or primary hepatocellular carcinoma diagnosed by pathological histology or cytology examination, and at least one measurable lesions (according to the RECIST1.1 standard, the spiral CT scan of 10mm or short diameter of 15mm）；\n3. Patients without previous systematic treatment and inoperable resection \u002F radical ablation surgery, but who can tolerate TACE;\n4. The CNLC stage is Ⅱa-Ⅲb stage;\n5. The Child-Pugh grade of liver function is A grade or B grade (5-7 points);\n6. The ECOG PS score is 0-1 points;\n7. Expected survival period of 12 weeks;\n8. If the patient has active hepatitis B virus (HBV) infection: HBV-deoxyribonucleic acid (DNA) must be \\\u003C2000 IU \u002F mL (if the study site has only copy \u002F mL testing units, Must be \\\u003C12500 copy \u002F mL), And received at least 14 days before initiating anti-HBV treatment (according to local standard therapy, e. g. entecavir) and willing to receive antiviral treatment throughout the study; hepatitis C virus (HCV) ribonucleic acid (RNA) positive patients must receive antiviral treatment according to local standard treatment guidelines and liver function within grade CTCAE 1 elevation;\n9. Main organs function are normal and meet the following criteria: (1) The blood routine examination standards should be met with: (no blood transfusion within 14 days) A. Hemoglobin (HB), 90g \u002F L, B. White blood cell count (WBC) 3109 \u002F L C. Absolute neutrophil count (ANC) 1.5109 \u002F L, D. Platelet (PLT) 80109 \u002F L;(2) Biochemical examination shall meet the following standards: A. Bilirubin (BIL) \\\u003C1.5 times the upper limit of normal value (ULN); B. Glutamic gamma aminotransferase (ALT) and glutamate aminotransferase AST \\\u003C5 ULN; C. Serum creatinine (Cr)≤1.5ULN；\n10. Women of childbearing age must have negative pregnancy test (serum) or urine HCG within 7 days before enrollment and are willing to use appropriate contraception during treatment and 24 weeks after the last administration of test drug; for men, surgical sterilization or agree to use appropriate contraception during and 24 weeks after the last administration of trial drug;\n11. The subjects volunteered to join the study and had good compliance with the follow-up.\n\nExclusion Criteria:\n\n1. Pregnant or lactating women;\n2. The pathology is clearly cholangiocytic carcinoma or mixed cell carcinoma;\n3. Diffuse liver cancer;\n4. Patients with autoimmune diseases, organ \u002F hematopoietic stem cell transplantation or other malignant tumors (except for cured basal skin cell carcinoma and cervix carcinoma in situ);\n5. Patients with consciousness disorders or unable to cooperate with the treatment, combined with patients with mental illness;\n6. Patients who have participated in other clinical trials in the recent three months;\n7. Previous history of other malignancies or have received targeted therapy and other PD-1 \u002F PD-L1 inhibitor therapy;\n8. Received major surgery or chemotherapy or other systemic therapy for target lesions (including not limited to radiation therapy, ablation therapy, etc.) within 1 month prior to enrollment;\n9. Use of immunosuppressants or systemic hormone therapy within 14 days before enrollment to achieve immunosuppressive purposes (dose\\> 10mg \u002F day prednisone or other efficacy hormones);\n10. Liver function was graded as Child-Pugh C, which could not be improved by liver care treatment；\n11. esophageal (gastric fundus) varices rupture and bleeding within 1 month before treatment；\n12. Uncorrectable coagulopathy and severe blood abnormalities, with severe bleeding tendency. Platelet count \\\u003C50109 \u002F L and severe coagulation abnormalities against surgery (anticoagulation therapy and \u002F or anticoagulant therapy should be stopped for more than 1 week before radiation therapy);\n13. A stubborn amount of ascites, pleural fluid, malignant fluid;\n14. Active infection, especially the inflammation of the biliary tract system;\n15. Severe functional failure of the liver, kidney, heart, lung, brain and other major organs;\n16. Previously allergic to PD-1 \u002F PD-L1 mAb \u002F any component of the targeted drug or other similar trials;\n17. Patients with hypertension who cannot be reduced to the normal range by antihypertensive medication (systolic blood pressure\\> 140 mmHg, diastolic blood pressure\\> 90 mmHg);\n18. Previous severe cardiovascular disease, including but not limited to the following diseases: myocardial ischemia or myocardial infarction, poorly controlled arrhythmia (including 450 ms in QTc men and 470 ms in women); cardiac dysfunction by NYHA, or cardiac ultrasound indicating left ventricular ejection fraction (LVEF) \\\u003C50%;\n19. Patients with positive urinary protein (urinary protein test of 2 + or above, or 24-hour urinary protein quantification of\\> 1.0g);\n20. Failure to swallow tablets, malabsorption syndrome, or any condition affecting gastrointestinal absorption;\n21. According to the discretion of the investigator, patients with other concomitant diseases that seriously endanger patient safety or affect the completion of the study;\n22. Patients with radiotherapy, targeted therapy, and other contraindications to immunotherapy.",{"count":274,"type":19},71,[22],"To evaluate the efficacy and safety of TACE combined with adebrelimab and bevacizumab transformation in unresectable hepatocellular carcinoma",[278,279,280,26,281],"Adebrelimab","Hepatocellular Carcinoma","Transformation","TACE","2024-02-27",{"date":284,"type":32},"2024-02-28",{"date":286,"type":32},"2023-11-15",{"date":288,"type":19},"2026-11-15",{"name":290,"class":39},"The First Affiliated Hospital of Xiamen University",{"id":292,"slug":293,"hasResults":11,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":4,"eligibilityCriteria":297,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":221,"enrollmentInfo":298,"targetDuration":4,"studyType":20,"phases":300,"briefSummary":301,"conditions":302,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":151},"100536478","cryoablation-combined-with-cardonilizumab-and-bevacizumab-in-hepatocellular-carcinoma-with-pulmonary-metastases-100536478","NCT06265350","Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases","Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases: A Single-center, Prospective, Randomized Controlled Phase II Study","Inclusion Criteria:\n\n1. primary or recurrent HCC;\n2. synchronous metastases (within one month after diagnosing of HCC) or asynchronous metastases (more than one month after diagnosis of HCC);\n3. pulmonary-only metastases \\>5 and ≤10;\n4. metastases diameter ≤ 5 cm;\n5. intrahepatic tumors ≤5, and tumor burden ≤1\u002F2 liver volume;\n6. PVTT type Vp≤3;\n7. patients underwent first-line system therapy failure, the first-line system included tyrosine kinase inhibitor (TKI), such as Sorafenib or Lenvatinib, with or without PD-1 or PDL1 inhibitor;\n8. the intrahepatic tumors were effectively controlled and pulmonary metastases were no progression, and the controlled intrahepatic tumors were defined as partial or stable response according to modified Response Evaluation Criteria in Solid Tumors (mRECIST);\n9. locoregional therapy (including TACE or HAIC) were also included;\n10. Child-Pugh class A or B;\n11. PS 0 or 1;\n12. no history of other malignancies.\n\nExclusion Criteria:\n\n1. under 18 years or over 75 years;\n2. metastases \\>10\n3. non-lung metastases;\n4. incomplete clinical data;\n5. metastases diameter \\> 5 cm;\n6. intrahepatic tumors \\> 5, and tumor burden \\> 1\u002F2 liver volume;\n7. PVTT type Vp 4;\n8. lost to follow-up within 3 months.",{"count":299,"type":19},80,[225],"This study intends to evaluate the efficacy and safety of cryoablation combined with Cardonilizumab and Bevacizumab in hepatocellular carcinoma with pulmonary metastases.",[279,303,304,305,26,306],"Liver Cancer Stage IV","Pulmonary Metastases","Cadonilimab","Cryoablation","2024-02-09",{"date":309,"type":32},"2024-02-20",{"date":311,"type":32},"2024-02-02",{"date":313,"type":19},"2027-01-30",{"name":69,"class":39},{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":322,"targetDuration":4,"studyType":20,"phases":324,"briefSummary":325,"conditions":326,"keywords":333,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":96},"100513809","phase-2-xelox-bev-tislelizumab-for-first-line-treatment-of-msspmmr-ras-mutated-mcrc-100513809","NCT05970302","XELOX +Bev +Tislelizumab for First-line Treatment of MSS\u002FpMMR RAS-mutated mCRC","XELOX and Bevacizumab in Combination With Tislelizumab for First-Line Treatment of Patients With MSS\u002FpMMR RAS-mutated Metastatic Colorectal Cancer (mCRC): A Single-arm, Phase II Study.","Inclusion Criteria:\n\n1. Histologically confirmed initially unresectable MSS\u002FpMMR-type RAS-mutant metastatic colorectal adenocarcinoma;\n2. ECOG score of 0 or 1;\n3. Ability to swallow oral medications;\n4. Have at least one measurable lesion (according to RECIST v1.1 standard);\n5. No anti-tumor treatment has been received after recurrence and metastasis;\n6. Neoadjuvant or adjuvant chemotherapy containing fluorouracil drugs is allowed before or after radical resection of colorectal cancer, but the treatment needs to be completed for ≥ 6 months; if oxaliplatin is used in neoadjuvant or adjuvant chemotherapy, it includes The oxaliplatin regimen needs to be completed for ≥12 months;\n7. Adequate organ function: On the premise of no component blood transfusion within 14 days: white blood cells ≥ 3.5\\*10\\^9\u002FL and neutrophils ≥ 1.5\\*10\\^9\u002FL, hemoglobin ≥ 90g\u002FL, platelets ≥ 100\\* 10\\^9\u002FL; serum bilirubin ≤ 1.5 times the normal value, alanine aminotransferase (ALT) ≤ 2.5 times the normal value, aspartate aminotransferase (AST) ≤ 2.5 times the normal value; Urinary protein \\\u003C2+. Or urine protein 2+ but 24-hour urine protein quantity ≤ 1 g; serum creatinine ≤ 1.5 times of normal value, creatinine clearance rate ≥ 60ml\u002Fmin; Doppler ultrasound evaluation: left ventricular ejection fraction (LVEF) ≥ lower limit of normal value (50%);\n8. Expected survival period ≥ 3 months;\n9. Patients fully understand this research, voluntarily participate in this clinical trial and sign an informed consent;\n10. Women with reproductive potential (\\\u003C 2 years after the last menstrual period) and men use effective contraceptive methods until half a year after the last treatment.\n\nExclusion Criteria:\n\n1. Previously received bevacizumab or anti-CTLA4, anti-PD-1\u002FPD-L1 therapeutic antibodies or pathway-targeted drugs;\n2. Received radiotherapy within 4 weeks before the evaluation;\n3. Symptomatic peripheral neuropathy \\> grade 2 (CTCAE5.0 standard);\n4. Received live vaccine or systemic immune stimulant (including but not limited to interferon or interleukin 2) within 1 month;\n5. HIV-positive and other immunodeficiency diseases;\n6. Active hepatitis B or hepatitis C (except for those who have been infected or cured before, that is, HBsAg negative and hepatitis B core antigen anti-HBc antibody positive; except for hepatitis C patients whose HCV RNA is negative by PCR);\n7. Existing autoimmune diseases or other diseases that require immunosuppressant treatment, except for type 1 diabetes; except for hypothyroidism that only requires hormone replacement therapy; skin diseases that do not require systemic treatment (such as vitiligo, psoriasis, alopecia areata); inhaled or topical steroids or equivalent steroids in excess of 10 mg prednisone per day, except for inactive autoimmune disease on adrenal replacement therapy;\n8. Received systemic hormone therapy or treatment with a daily dose of more than 10 mg prednisone equivalent dose or other forms of immunosuppressive treatment within 7 days, but inhaled or topical steroids or daily application of more than 10 mg prednisone, etc. Except for inactive autoimmune diseases treated with adrenal replacement therapy with potent steroids;\n9. Have a history of organ transplantation;\n10. Uncontrolled central nervous system (CNC) metastasis (symptomatic or metastatic sites are midbrain, pons, medulla or spinal cord) or other central nervous system diseases;\n11. Those who have undergone major surgery, open biopsy or obvious traumatic trauma within 1 month, or who may need major surgery during the study period; those who have undergone open biopsy or obvious traumatic trauma, or may need major surgery during the study period;\n12. Combined with other malignant tumors other than intestinal cancer (except cured basal cell carcinoma or squamous cell carcinoma of the skin and carcinoma in situ of the cervix; the treatment of other malignant tumors has been completed for more than 1 year, and there is no clinical and imaging evidence of recurrence or progression except);\n13. Combined active and refractory infection;\n14. Cardiovascular diseases with clinical significance, such as cardiovascular accident (CVA) (≤ 6 months before treatment), myocardial infarction (≤ 6 months before treatment), unstable angina, chronic heart failure of NYHA ≥ 2 (CHF), uncontrolled arrhythmia; uncontrolled hypertension; thromboembolic or bleeding events within 6 months before treatment;\n15. Evidence of causing coagulation disease;\n16. With dysphagia, active peptic ulcer, complete or incomplete intestinal obstruction, active gastrointestinal bleeding, perforation, malabsorption syndrome or uncontrollable gastrointestinal inflammatory disease (such as Crohn's disease or ulcerative colon inflammation);\n17. Severe unhealed wounds\u002Fulcers or severe fractures;\n18. Any serious acute or chronic medical condition that may affect the patient's participation in the study or interfere with the interpretation of the study results;\n19. There are mental illnesses, serious social and psychological illnesses, or researchers believe that there are factors that may affect research compliance;\n20. Pregnant or lactating women;\n21. No therapeutic anticoagulant or antiplatelet drugs or NSAIDs (aspirin ≤ 325 mg\u002Fday allowed);\n22. Severe allergic reaction to the test drug;\n23. Reluctance to use alternative therapies such as (but not limited to) bisphosphonates if receiving RANKL inhibitors (eg, denosumab).",{"count":323,"type":19},52,[22],"The goal of this clinical trial is to compare XELOX +Bev +Tislelizumab with standard chemotherapy，in MSS\u002FpMMR-type RAS-mutated metastatic colorectal adenocarcinoma. The main questions it aims to answer are efficacy and safety of the regimen of XELOX +Bev +Tislelizumab. The investigators want to transform ras-mutated colorectal cancer into a \"hot tumor\" through the combination of anti-vascular therapy and chemotherapy, and then achieve better therapeutic effect through the combination with immunotherapy. Participants will receive the regimen of XELOX +Bev +Tislelizumab.",[114,26,327,328,329,330,331,332],"Oxaliplatin","Capecitabine","MSS\u002FpMMR","Metastatic Colorectal Cancer (mCRC)","RAS-mutated","First-Line",[334,335],"Single-arm","Phase II","2023-07-21",{"date":338,"type":32},"2023-08-01",{"date":340,"type":32},"2023-07-07",{"date":342,"type":19},"2026-07",{"name":344,"class":39},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences"]